Germany granted SPC for Galliprant® on June 26, 2019, a veterinary drug product developed by
Aratana Therapeutics Inc. (Aratana), and marketed by Aratana and Elanco Animal Health Inc.
(Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28,
2031. Additional SPCs for Galliprant® are currently under examination in several major EU
countries. The grant in France marks the fifth approval in the EU, following grants received in Italy,
Holland, Spain and Germany.

Galliprant®
Galliprant® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist for the control
of pain and inflammation associated with osteoarthritis in dogs. Galliprant® has been granted
marketing authorization by the European Commission on January 11, 2018 and Elanco launched the
sales on April 2019.  

 
Supplementary Protection Certificate (SPC)
In major countries around the world, a patent generally expires after 20 years following submission
of the patent application. However, the patent exclusivity periods for pharmaceuticals may be
extended for a maximum of five years in order to compensate for the time consuming and costly
research and development. The SPC grant by France for Galliprant® represents a five-year
extension of the therapy’s exclusive sales period.